Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding La Jolla Pharmaceutical Company is 'Buy'. Macroaxis provides La Jolla buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding La Jolla positions. The advice algorithm takes into account all of La Jolla Pharmaceutical available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from La Jolla buy-and-hold prospective. Please see also La Jolla Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.
For the selected time horizon La Jolla Pharmaceutical Company has a risk adjusted performance of 0.1854, jensen alpha of 0.5053, total risk alpha of 0.6267, sortino ratio of 0.2571 and treynor ratio of 2.64Our buy or sell recommendation tool can be used to cross verify current analyst consensus on La Jolla Pharmaceutical Company and to analyze the entity potential to grow in the coming quarters. To make sure La Jolla Pharmaceutical is not overpriced, please verify all La Jolla Pharmaceutical Company fundamentals including its Shares Owned by Insiders, EBITDA, Short Ratio, as well as the relationship between Price to Book and Total Debt . Given that La Jolla Pharmaceutical has Price to Earning of (6.45)X, we recommend you check La Jolla market performance and probability of bankruptcy to make sure the company can sustain itself in the coming quarters given your latest risk tolerance and investing horizon.
La Jolla Trading Alerts and Improvement Suggestions
La Jolla Pharmaceutical Company currently demonstrates below average downside deviation of 2.11. It has Information Ratio of 0.21 and Jensen Alpha of 0.51. However, we do advice investors to further question La Jolla Pharmaceutical Company expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.